Autoantibodies in COVID-19 convalescent plasma donors.

ABSTRACT:

Background and objectives

Although COVID-19 convalescent plasma (CCP) has been successfully used to treat several viral infections, its effectiveness in neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its broader immunological safety remain debated. Since viral infections can trigger autoimmunity, particularly through molecular mimicry and immune dysregulation, there is growing interest in understanding whether CCP contains autoantibodies that could affect recipient safety.

Materials and methods

In this study, we evaluated the presence of 20 different autoantibodies, along with anti-SARS-CoV-2 antibodies, in plasma samples from CCP donors. Samples were collected at three time intervals following COVID-19 symptom onset: 0-60, 60-120 and 120-180 d

SUBMITTER: Jazbec Gradisar K 

PROVIDER: S-EPMC12803771 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature